Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
12:11pm, Sunday, 31'st May 2026
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
04:01pm, Thursday, 28'th May 2026
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today an
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
09:05am, Tuesday, 26'th May 2026
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the
Editas Medicine Announces Proposed Public Offering
06:15am, Tuesday, 26'th May 2026
CAMBRIDGE, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced th
Editas Medicine Announces Proposed Public Offering
06:15am, Tuesday, 26'th May 2026
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced tha
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent eff
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months New data demonstrate promising precl
EDIT's Q1 Loss Narrower Than Expected, Pipeline in Focus
01:01pm, Wednesday, 06'th May 2026
Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo gene editing and lead candidate EDIT-401.
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
09:26am, Tuesday, 05'th May 2026
Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.43 per share a year ago.
Editas Medicine Announces First Quarter 2026 Results and Business Updates
07:00am, Tuesday, 05'th May 2026
EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026 Company to present new EDIT-401 preclinical data
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Monday, 13'th Apr 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of “Moderate Buy” from Analysts
02:18am, Monday, 13'th Apr 2026
Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have received an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One analyst
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 08'th Apr 2026
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
JPMorgan Chase & Co. Has $2.85 Million Position in Editas Medicine, Inc. $EDIT
04:46am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange C
